Coating nanoparticles with cell membranes for targeted drug delivery

Journal of Drug Targeting

Volumn 23, Issue 7-8, 2015, Pages 619-626

  Gao, Weiwei ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomimetic nanoparticle; cell membrane; drug delivery; nanomedicine; vaccination

Indexed keywords

NANOPARTICLE; BIOMIMETIC MATERIAL;

ARTICLE; BACTERIAL MEMBRANE; CELL MEMBRANE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; ANIMAL; DRUG DESIGN; METABOLISM;

ANIMALS; BIOMIMETIC MATERIALS; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOPARTICLES;

EID: 84944217271     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2015.1052074     Document Type: Article

References (81)

1. Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 2014;9:223-43
2. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 2014;13:655-72
3. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000;11:S81-S91
4. Chertok B, Webber MJ, Succi MD, Langer R. Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies. Mol Pharm 2013;10:3531-43
5. Langer R. New methods of drug delivery. Science 1990;249: 1527-33
6. Langer R. Drug delivery and targeting. Nature 1998;392:5-10
7. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20
8. Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010;10:3223-30
9. Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a psma-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012; 4:article 128ra39
10. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58:1456-9
11. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60
12. Alexis F, Rhee J-W, Richie JP, et al. New frontiers in nanotechnology for cancer treatment. Urol Oncol Semin Ori 2008;26:74-85
13. Luk BT, Zhang L. Current advances in polymer-based nanotheranostics for cancer treatment and diagnosis. ACS Appl Mater Interfaces 2014;6:21859-73
14. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 2001;53: 283-318
15. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185-98
16. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15
17. Barua S, Mitragotri S. Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles. ACS Nano 2013;7:9558-70
18. Kolhar P, Anselmo AC, Gupta V, et al. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci USA 2013;110:10753-8
19. Barua S, Yoo J-W, Kolhar P, et al. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc Natl Acad Sci USA 2013;110:3270-5
20. Lee H, Lytton-Jean AKR, Chen Y, et al. Molecularly selfassembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol 2012;7:389-93
21. Kamaly N, Fredman G, Subramanian M, et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci USA 2013;110:6506-11
22. Leserman LD, Barbet J, Kourilsky F, Weinstein JN. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein-a. Nature 1980;288:602-4
23. Heath TD, Fraley RT, Papahadjopoulos D. Antibody targeting of liposomes - cell specificity obtained by conjugation of f(ab')2 to vesicle surface. Science 1980;210:539-41
24. Farokhzad OC, Cheng JJ, Teply BA, et al. Targeted nanoparticleaptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-20
25. Valencia PM, Hanewich-Hollatz MH, Gao W, et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 2011;32: 6226-33
26. Farokhzad OC. Using ligands to target cancer cells. Clin Adv Hematol Oncol 2012;10:543-4
27. Gao W, Chan JM, Farokhzad OC. Ph-responsive nanoparticles for drug delivery. Mol Pharm 2010;7:1913-20
28. Radovic-Moreno AF, Lu TK, Puscasu VA, et al. Surface chargeswitching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano 2012;6:4279-87
29. Choi WI, Kamaly N, Riol-Blanco L, et al. A solvent-free thermosponge nanoparticle platform for efficient delivery of labile proteins. Nano Lett 2014;14:6449-55
30. Zhang L, Gu FX, Chan JM, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008;83:761-9
31. Veiseh O, Tang BC, Whitehead KA, et al. Managing diabetes with nanomedicine: challenges and opportunities. Nat Rev Drug Discov 2015;14:45-57
32. Schroeder A, Heller DA, Winslow MM, et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012;12:39-50
33. Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res 2011;44:1123-34
34. Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012;41:2971-3010
35. Matsumura Y, Gotoh M, Muro K, et al. Phase i and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in peg immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004;15:517-25
36. Phan A, Takimoto C, Adinin R, et al. Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors. Mol Cancer Ther 2007;6: 3563S
37. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70
38. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6:659-68
39. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature 2004;428:487-92
40. Wegst UGK, Bai H, Saiz E, et al. Bioinspired structural materials. Nat Mater 2015;14:23-36
41. Irvine DJ, Swartz MA, Szeto GL. Engineering synthetic vaccines using cues from natural immunity. Nat Mater 2013;12:978-90
42. Najer A, Wu D, Bieri A, et al. Nanomimics of host cell membranes block invasion and expose invasive malaria parasites. ACS Nano 2014;8:12560-71
43. Balmert SC, Little SR. Biomimetic delivery with micro- and nanoparticles. Adv Mater 2012;24:3757-78
44. Hu C-MJ, Zhang L, Aryal S, et al. Erythrocyte membranecamouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA 2011;108:10980-5
45. Hu C-MJ, Fang RH, Copp J, et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol 2013;8:336-40
46. Hu C-MJ, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol 2013;8: 933-8
47. Gao W, Zhang L. Engineering red blood cell membrane-coated nanoparticles for broad biomedical applications. AIChE J 2015;61: 738-46
48. Gao W, Hu C-MJ, Fang RH, Zhang L. Liposome-like nanostructures for drug delivery. J Mater Chem B 2013;1:6569-85
49. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7:771-82
50. Hu C-MJ, Fang RH, Luk BT, Zhang L. Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale 2014;6:65-75
51. Hu C-MJ, Fang RH, Zhang L. Erythrocyte-inspired delivery systems. Adv Healthc Mater 2012;1:537-47
52. Wu Z, Li T, Li J, et al. Turning erythrocytes into functional micromotors. ACS Nano 2014;8:12041-8
53. Muzykantov VR. Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 2010;7: 403-27
54. Luk BT, Hu C-MJ, Fang RH, et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 2014;6:2730-7
55. Rodriguez PL, Harada T, Christian DA, et al. Minimal ''self'' peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science 2013;339:971-5
56. Hu C-MJ, Fang RH, Luk BT, et al. 'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach. Nanoscale 2013;5:2664-8
57. Gao W, Langer R, Farokhzad OC. Poly(ethylene glycol) with observable shedding. Angew Chem Int Ed 2010;49: 6567-71
58. Gao W, Hu C-MJ, Fang RH, et al. Surface functionalization of gold nanoparticles with red blood cell membranes. Adv Mater 2013;25: 3549-53
59. Piao J-G, Wang L, Gao F, et al. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. ACS Nano 2014;8:10414-25
60. Li L-L, Xu J-H, Qi G-B, et al. Core-shell supramolecular gelatin nanoparticles for adaptive and ''on-demand'' antibiotic delivery. ACS Nano 2014;8:4975-83
61. Copp JA, Fang RH, Luk BT, et al. Clearance of pathological antibodies using biomimetic nanoparticles. Proc Natl Acad Sci USA 2014;111:13481-6
62. Gu F, Zhang L, Teply BA, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008;105:2586-91
63. Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of fctargeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 2013;5:article 213ra167
64. Fang RH, Hu C-MJ, Chen KNH, et al. Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. Nanoscale 2013;5:8884-8
65. Fang RH, Hu C-MJ, Luk BT, et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett 2014;14:2181-8
66. Khaldoyanidi SK, Glinsky VV, Sikora L, et al. Mda-mb-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by thomsenfriedenreich antigen-galectin-3 interactions. J Biol Chem 2003; 278:4127-34
67. Glinsky VV, Glinsky GV, Glinskii OV, et al. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res 2003;63:3805-11
68. Overwijk WW, Theoret MR, Finkelstein SE, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+T cells. J Exp Med 2003;198: 569-80
69. GaoW, Fang RH, Thamphiwatana S, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett 2015;15:1403-9
70. Jewell CM, Lopez SCB, Irvine DJ. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvantreleasing polymer particles. Proc Natl Acad Sci USA 2011;108: 15745-50
71. Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 2007;25:1159-64
72. Liu H, Moynihan KD, Zheng Y, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 2014;507: 519-22
73. Moon JJ, Suh H, Bershteyn A, et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011;10:243-51
74. Moon JJ, Suh H, Li AV, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand t-fh cells and promote germinal center induction. Proc Natl Acad Sci USA 2012;109:1080-5
75. Hu C-MJ, Zhang L. Nanotoxoid vaccines. Nano Today 2014;9: 401-4
76. Kennedy AD, Wardenburg JB, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of usa300 skin infection in a mouse model. J Infect Dis 2010;202:1050-8
77. Kernodle DS. Expectations regarding vaccines and immune therapies directed against staphylococcus aureus alpha-hemolysin. J Infect Dis 2011;203:1692-3
78. Fan Z, Zhou H, Li PY, et al. Structural elucidation of cell membrane-derived nanoparticles using molecular probes. J Mater Chem B 2014;2:8231-8
79. Parodi A, Quattrocchi N, van de Ven AL, et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol 2013;8: 61-8
80. Johannes L, Roemer W. Shiga toxins - from cell biology to biomedical applications. Nat Rev Microbiol 2010;8: 105-16
81. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 2014;12:535-49